Brovanetics

Our Breast and Ovarian Cancer Gene Panel


North Central Florida Diagnostics & DNA Technologies (NCF DNA) offers genetic testing to identify individuals who are predisposed to a genetic mutation for inherited breast and ovarian cancer. Next Generation Sequencing allows the identification of high-risk individuals and provides a key to early diagnosis of cancer and proactive care.

Using targeted genomic Next Generation Sequencing, we screen for germ-line mutations in 15 genes identified as conferring high risk for cancer as seen in women with breast and ovarian carcinoma. This is a sub-panel of our comprehensive panel.

Our BrovaneticsTM panel consists of the following genes: ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, RAD51C, RET, STK11, TP53, VHL.

The most widely recognized risk factor for breast cancer is having a positive family history. An individual’s lifetime risk increases with family history. Risk factors include: 1) a first-degree relative, like a mother or sister 2) multiple family members with breast and/or ovarian cancer.  Both males and females can inherit and transmit an autosomal dominant cancer predisposition gene. Additional factors increasing risk, coupled with family history, include a personal history of any cancer, use of oral contraceptives, hormone replacement, radiation exposure, and alcohol usage.